Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
Ligand Pharmaceuticals (LGND) has announced it will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis, along with senior management and board members, will participate in the ceremony to celebrate recent company milestones, including two value-creating transactions.
Davis highlighted Ligand's transformation into a profitable, infrastructure-light organization that focuses on acquiring and generating royalties from a diverse biopharmaceutical product portfolio. The company aims to continue building on its two-year momentum, supporting partner development of breakthrough medicines, and creating long-term shareholder value. The ceremony will be broadcast live at 9:15 a.m. Eastern Time.
Ligand Pharmaceuticals (LGND) ha annunciato che suonerà la campanella di apertura del Nasdaq Stock Market lunedì 19 maggio 2025. Il CEO Todd Davis, insieme ai dirigenti senior e ai membri del consiglio, parteciperà alla cerimonia per celebrare i recenti traguardi aziendali, inclusi due accordi che hanno creato valore.
Davis ha sottolineato la trasformazione di Ligand in un'organizzazione redditizia e con una struttura leggera, focalizzata sull'acquisizione e sulla generazione di royalties da un portafoglio diversificato di prodotti biofarmaceutici. L'azienda intende continuare a costruire sul momentum degli ultimi due anni, supportando lo sviluppo di farmaci innovativi da parte dei partner e creando valore a lungo termine per gli azionisti. La cerimonia sarà trasmessa in diretta alle 9:15 ora della costa orientale degli Stati Uniti.
Ligand Pharmaceuticals (LGND) ha anunciado que tocará la campana de apertura del Nasdaq Stock Market el lunes 19 de mayo de 2025. El CEO Todd Davis, junto con la alta dirección y miembros del consejo, participará en la ceremonia para celebrar los recientes hitos de la empresa, incluyendo dos transacciones que generaron valor.
Davis destacó la transformación de Ligand en una organización rentable y con una infraestructura ligera, enfocada en la adquisición y generación de regalías de un portafolio diverso de productos biofarmacéuticos. La compañía busca continuar construyendo sobre el impulso de los últimos dos años, apoyando el desarrollo de medicamentos innovadores por parte de sus socios y creando valor a largo plazo para los accionistas. La ceremonia será transmitida en vivo a las 9:15 a.m. hora del Este.
Ligand Pharmaceuticals (LGND)는 2025년 5월 19일 월요일 나스닥 증권거래소 개장 종을 울릴 예정이라고 발표했습니다. CEO Todd Davis와 고위 경영진 및 이사회 멤버들이 참석하여 최근 회사의 주요 성과, 특히 두 건의 가치 창출 거래를 기념하는 행사에 참여할 것입니다.
Davis는 Ligand가 수익성 있는 경량 인프라 조직으로 탈바꿈하여 다양한 생명공학 제품 포트폴리오에서 로열티를 획득하고 생성하는 데 집중하고 있음을 강조했습니다. 회사는 지난 2년간의 모멘텀을 이어가며 파트너의 혁신적 의약품 개발을 지원하고 장기적인 주주 가치를 창출하는 데 주력할 계획입니다. 행사는 동부 표준시 기준 오전 9시 15분에 생중계됩니다.
Ligand Pharmaceuticals (LGND) a annoncé qu'elle sonnera la cloche d'ouverture du Nasdaq Stock Market le lundi 19 mai 2025. Le PDG Todd Davis, accompagné de la haute direction et des membres du conseil d'administration, participera à la cérémonie pour célébrer les récents jalons de l'entreprise, y compris deux transactions créatrices de valeur.
Davis a souligné la transformation de Ligand en une organisation rentable et légère en infrastructure, axée sur l'acquisition et la génération de redevances issues d'un portefeuille diversifié de produits biopharmaceutiques. L'entreprise vise à poursuivre sur sa dynamique de deux ans, en soutenant le développement par ses partenaires de médicaments innovants et en créant une valeur durable pour les actionnaires. La cérémonie sera diffusée en direct à 9h15, heure de l'Est.
Ligand Pharmaceuticals (LGND) hat angekündigt, dass es am Montag, den 19. Mai 2025, die Eröffnungsglocke an der Nasdaq Stock Market läuten wird. CEO Todd Davis sowie das Senior Management und Vorstandsmitglieder werden an der Zeremonie teilnehmen, um jüngste Unternehmensmeilensteine zu feiern, darunter zwei wertschöpfende Transaktionen.
Davis hob die Transformation von Ligand zu einer profitablen, infrastrukturschonenden Organisation hervor, die sich auf den Erwerb und die Generierung von Lizenzgebühren aus einem vielfältigen biopharmazeutischen Produktportfolio konzentriert. Das Unternehmen will auf dem zweijährigen Aufwärtstrend aufbauen, die Entwicklung bahnbrechender Medikamente durch Partner unterstützen und langfristigen Shareholder Value schaffen. Die Zeremonie wird um 9:15 Uhr Eastern Time live übertragen.
- None.
- None.
JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis will be joined by members of Ligand’s senior management team and board of directors to commemorate several recent company milestones, including two value-creating transactions.
“Ringing the Nasdaq Opening Bell marks an exciting milestone in our company’s history. Over the past few years, we have made significant progress in transforming Ligand into a profitable and infrastructure-light organization focused on acquiring and generating royalties from a diverse portfolio of biopharmaceutical products,” said Todd Davis, CEO of Ligand. “Looking ahead, we remain committed to building on the momentum we’ve achieved over the past two years, supporting our partners in developing breakthrough medicines for patients, and creating long-term value for our shareholders.”
The live broadcast of the Nasdaq Opening Bell ceremony will begin at 9:15 a.m. Eastern Time and will be available at https://www.nasdaq.com/marketsite/bell-ringing-ceremony.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
When will Ligand Pharmaceuticals (LGND) ring the Nasdaq Opening Bell?
What has Ligand Pharmaceuticals (LGND) achieved in recent years?
Who will represent Ligand (LGND) at the Nasdaq bell ringing ceremony?
Where can I watch Ligand's (LGND) Nasdaq Opening Bell ceremony?
